# US 2026/0061020 A1 · Butyrate- & curcuminoid-containing compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061020 A1
- Document ID: US20260061020A1
- Status: Published application
- Kind: A1
- Application number: 19/171,446
- Filed: 2025-04-07
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Inventors: Franco Cavaleri
- Web page: https://patentgrep.com/patent/US20260061020A1

## CPC

- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 31/12: Ketones
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids and turmeric extracts (and/or curcuminoids) are disclosed. The compositions include purified butyrate and dried turmeric extracts. The compositions may optionally include purified butyrate and dried turmeric extracts spiked with additional curcumin I, curcumin II, and/or curcumin III. Alternatively, the compositions may include short chain fatty acids (such as butyrate) and purified curcumin I, curcumin II, and/or curcumin III.

## Claims

### Claim 1

A composition comprising:
(a) purified butyrate or salts thereof, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, and/or a butyrate magnesium salt; and
(b) dried turmeric extract.

### Claim 2

A composition comprising:
(a) purified butyrate or salts thereof, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, and/or a butyrate magnesium salt; and
(b) dried turmeric extract, wherein the dried turmeric extract contains elevated levels of curcumin I, curcumin II, and/or curcumin III.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the dried turmeric extract includes at least 50% (w/w) of bisdemethoxycurcumin (curcumin III).

### Claim 4

A composition comprising:
(a) purified butyrate or salts thereof, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, and/or a butyrate magnesium salt; and
(b) purified curcumin I, curcumin II, and/or curcumin III.

### Claim 5 (depends on 1)

A method for reducing inflammation in a group of cells that comprises administering to the cells an effective amount of the composition of claim 1.

### Claim 6 (depends on 2)

A method for reducing inflammation in a group of cells that comprises administering to the cells an effective amount of the composition of claim 2.

### Claim 7 (depends on 3)

A method for reducing inflammation in a group of cells that comprises administering to the cells an effective amount of the composition of claim 3.

### Claim 8 (depends on 4)

A method for reducing inflammation in a group of cells that comprises administering to the cells an effective amount of the composition of claim 4.

### Claim 9 (depends on 1)

A method for reducing expression of TNF-α in a group of cells that comprises administering to the cells an effective amount of the composition of claim 1.

### Claim 10 (depends on 2)

A method for reducing expression of TNF-α in a group of cells that comprises administering to the cells an effective amount of the composition of claim 2.

### Claim 11 (depends on 3)

A method for reducing expression of TNF-α in a group of cells that comprises administering to the cells an effective amount of the composition of claim 3.

### Claim 12 (depends on 4)

A method for reducing expression of TNF-α in a group of cells that comprises administering to the cells an effective amount of the composition of claim 4.

### Claim 13 (depends on 1)

A method for reducing expression of IL-8 in a group of cells that comprises administering to the cells an effective amount of the composition of claim 1.

### Claim 14 (depends on 2)

A method for reducing expression of IL-8 in a group of cells that comprises administering to the cells an effective amount of the composition of claim 2.

### Claim 15 (depends on 3)

A method for reducing expression of IL-8 in a group of cells that comprises administering to the cells an effective amount of the composition of claim 3.

### Claim 16 (depends on 4)

A method for reducing expression of IL-8 in a group of cells that comprises administering to the cells an effective amount of the composition of claim 4.
